Editas Medicine, Inc. Stock

$2.54

1.17%

Nasdaq, Jul 07, 10:02 pm CET

ISIN

US28106W1036

Symbol

EDIT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Editas Medicine, Inc. Stock price

$2.54

-29.63 92.10% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-0.03 1.17%

ISIN

US28106W1036

Symbol

EDIT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$215.1m

Enterprise Value

$48.8m

Net debt

positive

Cash

$221.0m

Shares outstanding

83.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

6.0 | 17.0

EV/Sales

1.4 | 3.8

EV/FCF

negative

P/B

3.5

Financial Health

Equity Ratio

39.3%

Return on Equity

-176.6%

ROCE

-108.8%

ROIC

Debt/Equity

0.9

Financials (TTM | estimate)

Revenue

$35.8m | $12.7m

EBITDA

$-200.9m | $-160.3m

EBIT

$-207.2m | $-161.0m

Net Income

$-251.2m | $-153.6m

Free Cash Flow

$-215.3m

Growth (TTM | estimate)

Revenue

-48.4% | -60.8%

EBITDA

-12.1% | 31.3%

EBIT

-11.9% | -

Net Income

-51.2% | 35.2%

Free Cash Flow

-42.5%

EPS

$-3.0

FCF per Share

$-2.6

Short interest

10.1%

Employees

246

Rev per Employee

$130.0k

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

??

21 Analysts have issued a Editas Medicine, Inc. forecast:

10x Buy

48%

9x Hold

43%

More details on Analyst Estimates Including Price Targets

21 Analysts have issued a Editas Medicine, Inc. forecast:

Buy

48%

Hold

43%

Sell

10%

Analyst Estimates with Stock Price Targets

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	36 36	48% 48% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	66 66	0% 0% 184%
- Research and Development Expense	177 177	6% 6% 494%
EBITDA	-201 -201	12% 12% -561%
- Depreciation and Amortization	6.32 6.32	7% 7% 18%
EBIT (Operating Income) EBIT	-207 -207	12% 12% -578%
Net Profit	-251 -251	51% 51% -701%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Editas Medicine, Inc. Stock News

Positive

The Motley Fool

●

10 days ago

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Investors looking for stocks that can produce dramatic gains in a short amount of time will want to turn their heads toward the biopharmaceutical space. Chasing short-term gains isn't the smartest way to invest, but hardly a month goes by without at least one stock from this industry shooting through the roof as the drugs it develops cross important milestones.

Negative

The Motley Fool

●

11 days ago

2 Beaten-Down Stocks to Avoid

Over the past year, Editas Medicine (EDIT -3.20%) and Sarepta Therapeutics (SRPT -1.38%), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period.

Neutral

The Motley Fool

●

21 days ago

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine (EDIT 6.94%) is a promising clinical-stage company that has captured Wall Street's attention at the forefront of the gene-editing revolution with a unique approach to CRISPR technologies.

More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Gilmore O’Neill
Employees	246
Founded	2013
Website	www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now